Distribution of individual disease-modifying therapies (DMTs) among participants of the COVID-19 study
| DMT | Total (n=3907), n (%) | Self-diagnosed COVID-19 (n=236), n (%) | Confirmed COVID-19 (n=37), n (%) |
| None | 2088 (53.4) | 116 (49.2) | 11 (29.7) |
| Beta-interferons* | 232 (5.9) | 11 (4.7) | 1 (2.7) |
| Glatiramer acetate* | 196 (5) | 18 (7.6) | 3 (8.1) |
| Dimethyl fumarate* | 446 (11.4) | 32 (13.6) | 7 (18.9) |
| Teriflunomide* | 93 (2.4) | 2 (0.8) | 0 (0) |
| Fingolimod* | 235 (6) | 15 (6.4) | 4 (10.8) |
| Siponimod | 3 (0.1) | 0 (0) | 0 (0) |
| Ocrelizumab† | 193 (4.9) | 14 (5.9) | 4 (10.8) |
| Natalizumab† | 231 (5.9) | 19 (8.1) | 5 (13.5) |
| Cladribine† | 73 (1.9) | 2 (0.8) | 0 (0) |
| Alemtuzumab† | 93 (2.4) | 5 (2.1) | 2 (5.4) |
| HSCT† | 2 (0.1) | 0 (0) | 0 (0) |
| Mitoxantrone† | 0 (0) | 0 (0) | 0 (0) |
| Others‡ | 16 (0.4) | 2 (0.8) | 0 (0) |
| Unknown | 6 (0.2) | 0 (0) | 0 (0) |
*Defined as moderate-efficacy DMTs.
†Defined as high-efficacy DMTs.
‡Including rituximab, ofatumumab, ublituximab, vedolizumab, ponesimod, azathioprine, mycophenolate mofetil and methotrexate.
HSCT, hematopoietic stem cell transplantation.